Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)

被引：8

作者：

Hasegawa, Tsukasa ^{[1
]}

Ariyasu, Ryo ^{[2
]}

Tanaka, Hisashi ^{[3
]}

Saito, Ryota ^{[4
]}

Kawashima, Yosuke ^{[5
]}

Horiike, Atsushi ^{[6
]}

Sakatani, Toshio ^{[7
]}

Tozuka, Takehiro ^{[8
]}

Shiihara, Jun ^{[9
]}

Saiki, Masafumi ^{[10
]}

Tambo, Yuichi ^{[11
]}

Sonoda, Tomoaki ^{[12
]}

Miyazaki, Akito ^{[13
]}

Uematsu, Shinya ^{[14
]}

Tsuchiya-Kawano, Yuko ^{[15
]}

Yanagitani, Noriko ^{[2
]}

Nishino, Makoto ^{[2
]}

机构：

[1] Jikei Univ, Dept Internal Med, Div Resp Dis, Daisan Hosp, Tokyo, Japan

[2] Canc Inst Hosp Japanese Fdn Canc Res, Dept Thorac Med Oncol, Tokyo, Japan

[3] Hirosaki Univ, Dept Resp Med, Grad Sch Med, Hirosaki, Japan

[4] Tohoku Univ Hosp, Dept Resp Med, Sendai, Japan

[5] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Japan

[6] Showa Univ, Dept Med, Div Med Oncol, Sch Med, Tokyo, Japan

[7] NTT Med Ctr, Div Resp, Tokyo, Japan

[8] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan

[9] Jichi Med Univ, Saitama Med Ctr, Dept Pulm Med, Saitama, Japan

[10] Univ Yamanashi, Grad Sch Med, Dept Resp Med, Yamanashi, Japan

[11] Kanazawa Univ, Dept Resp Med, Kanazawa, Japan

[12] Univ Fukui, Fac Med Sci, Dept Internal Med 3, Fukui, Japan

[13] Natl Hosp Org Osaka Toneyama Med Ctr, Dept Thorac Oncol, Osaka, Japan

[14] Osaka Red Cross Hosp, Dept Resp Med, Osaka, Japan

[15] Kitakyushu Municipal Med Ctr, Dept Resp Med, Kitakyushu, Japan

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2023年 / 92卷 / 01期

关键词：

Stage III non-small-cell lung cancer; Durvalumab; Chemoradiotherapy; Subsequent treatment; CHEMOTHERAPY; RADIOTHERAPY; CRITERIA;

D O I：

10.1007/s00280-023-04547-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PurposeFor patients with locally advanced non-small-cell lung cancer (LA-NSCLC) that progressed after definitive chemoradiotherapy (CRT) and durvalumab consolidation therapy, no subsequent standard treatment exists. The type of treatment selected for each timing of disease progression and its efficacy have not been investigated.MethodsWe retrospectively enrolled patients with LA-NSCLC or inoperable NSCLC that progressed after definitive CRT and durvalumab consolidation therapy at 15 Japanese institutions. Patients were classified into the following: Early Discontinuation group (disease progression within 6 months after durvalumab initiation), Late Discontinuation group (disease progression from 7 to 12 months after durvalumab initiation), and Accomplishment group (disease progression from 12 months after durvalumab initiation).ResultsAltogether, 127 patients were analyzed, including 50 (39.4%), 42 (33.1%) and 35 (27.5%) patients from the Early Discontinuation, Late Discontinuation, and Accomplishment groups, respectively. Subsequent treatments were Platinum plus immune checkpoint inhibitors (ICI) in 18 (14.2%), ICI in 7 (5.5%), Platinum in 59 (46.4%), Non-Platinum in 35 (27.6%), and tyrosine kinase inhibitor in 8 (6.3%) patients. In the Early Discontinuation, Late Discontinuation, and Accomplishment groups, 4 (8.0%), 7 (16.7%), and 7 (20.0%) patients were receiving Platinum plus ICI; 21 (42.0%), 22 (52.4%), and 16 (45.7%) were receiving Platinum, and 20 (40.0%), 8 (19.0%), and 7 (20.0%) were receiving Non-Platinum, respectively. No significant difference in progression-free survival was observed in the timing of disease progression.ConclusionIn patients with LA-NSCLC hat progressed after definitive CRT and durvalumab consolidation therapy, subsequent treatment may change depending on the timing of disease progression.

引用

页码：29 / 37

页数：9

共 14 条

[1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[2] Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer [J].

Auperin, Anne ;

Le Pechoux, Cecile ;

Rolland, Estelle ;

Curran, Walter J. ;

Furuse, Kiyoyuki ;

Fournel, Pierre ;

Belderbos, Jose ;

Clamon, Gerald ;

Ulutin, Hakki Cuneyt ;

Paulus, Rebecca ;

Yamanaka, Takeharu ;

Bozonnat, Marie-Cecile ;

Uitterhoeve, Apollonia ;

Wang, Xiaofei ;

Stewart, Lesley ;

Arriagada, Rodrigo ;

Burdett, Sarah ;

Pignon, Jean-Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2181-2190

[3] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[4] Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies [J].

Freites-Martinez, A. ;

Santana, N. ;

Arias-Santiago, S. ;

Viera, A. .

ACTAS DERMO-SIFILIOGRAFICAS, 2021, 112 (01) :90-92

[5] REINDUCTION CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER [J].

GIACCONE, G ;

FERRATI, P ;

DONADIO, M ;

TESTORE, F ;

CALCIATI, A .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (11) :1697-1699

[6] Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy [J].

Imai, Hisao ;

Kaira, Kyoichi ;

Mori, Keita ;

Ono, Akira ;

Akamatsu, Hiroaki ;

Taira, Tetsuhiko ;

Yoshino, Reiko ;

Kenmotsu, Hirotsugu ;

Saitoh, Jun-ichi ;

Harada, Hideyuki ;

Naito, Tateaki ;

Murakami, Haruyasu ;

Tomizawa, Yoshio ;

Matsuura, Masana ;

Saito, Ryusei ;

Nakajima, Takashi ;

Yamada, Masanobu ;

Takahashi, Toshiaki .

SPRINGERPLUS, 2015, 4

[7] Performance Status and Sensitivity to First-line Chemotherapy Are Significant Prognostic Factors in Patients With Recurrent Small Cell Lung Cancer Receiving Second-line Chemotherapy [J].

Kim, Young Hak ;

Goto, Koichi ;

Yoh, Kiyotaka ;

Niho, Seiji ;

Ohmatsu, Hironobu ;

Kubota, Kaoru ;

Saijo, Nagahiro ;

Nishiwaki, Yutaka .

CANCER, 2008, 113 (09) :2518-2523

[8] Immunotherapy rechallenge after nivolumab treatment in advanced non small cell lung cancer in the real-world setting: A national data base analysis [J].

Levra, Matteo Giaj ;

Cotte, Francois-Emery ;

Corre, Romain ;

Calvet, Christophe ;

Gaudin, Anne-Francoise ;

Penrod, John R. ;

Grumberg, Valentine ;

Jouaneton, Baptiste ;

Jolivel, Ronan ;

Assie, Jean-Baptiste ;

Chouaid, Christos .

LUNG CANCER, 2020, 140 :99-106

[9]

MARINO P, 1995, CANCER, V76, P593, DOI 10.1002/1097-0142(19950815)76:4<593::AID-CNCR2820760409>3.0.CO

[10]

2-N

← 1 2 →